Oxford, United Kingdom

Ewan Hunter

This inventor holds 10 USPTO granted patents and 8 published patent applications, plus 2 CIPO patents and 6 EPO patents. Top assignee: Oxford Biodynamics Plc. Active years: 2022-2026.

USPTO Granted Patents = 10 

% Patents Active = 100.0

 

 

Average Co-Inventor Count = 3.2

ph-index = 1


Company Filing History:


Years Active: 2022-2026

Loading Chart...
Loading Chart...
Loading Chart...
10 patents (USPTO):Explore Patents

Title: Ewan Hunter: Innovator in Genetic Research

Introduction

Ewan Hunter is a prominent inventor based in Oxford, GB. He has made significant contributions to the field of genetic research, holding a total of 8 patents. His work focuses on understanding complex genetic interactions and their implications for various diseases.

Latest Patents

Among his latest patents are "Detection of chromosome interactions as indicative of amyotrophic lateral sclerosis," which outlines a process for analyzing chromosome regions and interactions related to ALS and Huntington's disease. Another notable patent is "Genetic regulation of immunoresponse by chromosome interactions," which details a method for examining chromosome regions and interactions that influence immunoresponsiveness.

Career Highlights

Ewan Hunter is currently associated with Oxford Biodynamics Plc, where he applies his expertise in genetic research. His innovative approaches have positioned him as a key figure in the study of genetic interactions and their effects on health.

Collaborations

He has collaborated with notable colleagues, including Alexandre Akoulitchev and Aroul Selvam Ramadass, contributing to a dynamic research environment that fosters innovation.

Conclusion

Ewan Hunter's work in genetic research exemplifies the impact of innovative thinking in addressing complex health issues. His patents reflect a commitment to advancing our understanding of genetic interactions and their implications for diseases.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…